Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic

Financing accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team CAMBRIDGE, Mass.... Biopharmaceuticals, Oncology, Venture Capital Werewolf Therapeutics, tumor microenvironment, PREDATOR protein
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news